|Year : 2010 | Volume
| Issue : 1 | Page : 4-11
Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: Past, present, and future
Luigi Mearini, Massimo Porena
Department of Urology, University of Perugia, Italy
|Date of Web Publication||23-Mar-2010|
Department of Urology, University of Perugia, Perugia - 06100
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Upon a review of recently published articles on high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer, we evaluated the current status of HIFU as a primary treatment option for localized prostate cancer and its use as salvage therapy when radiation failed. We also briefly discuss current issues in indications, definition of response, and finally the future of HIFU development.
Keywords: High intensity focused ultrasound, prostate cancer, indications, outcomes
|How to cite this article:|
Mearini L, Porena M. Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: Past, present, and future. Indian J Urol 2010;26:4-11
|How to cite this URL:|
Mearini L, Porena M. Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: Past, present, and future. Indian J Urol [serial online] 2010 [cited 2020 Feb 28];26:4-11. Available from: http://www.indianjurol.com/text.asp?2010/26/1/4/60436
| Introduction|| |
Prostate cancer is with higher incidence in men,  and is the second leading cause of cancer mortality in industrialized countries. This high incidence has resulted in an increased number of patients requiring therapy. Widespread use of prostate-specific antigen (PSA) testing and the continuous efforts for early detection of early prostate cancer had increased the number of patients with localized prostate cancer, suitable to a curative approach.
The current management of localized prostate cancer could vary from expectant management (for men with low risk disease and a life-expectancy <10 years) to radical prostatectomy or radiation therapy with external beam radiotherapy (EBRT) in patients with a long life-expectancy, which represents gold standard of therapy in young men with localized prostate cancer.
Aim of cure is to enhance "quantity" of life, even if the increasing emphasis on achieving the best survival benefit while better preserving "quality of life" (in terms of side-effects, continence, and potency), the so called TRIFECTA, especially for the population aging and the incidence of low-grade prostate cancer, has led to the increased popularity of minimally invasive treatment, with the emergence of new nonsurgical therapeutic options for localized prostate cancer.
This refers to the use of a wide range of techniques for local target ablation of the prostate gland with minimal damage to the surrounding tissue. Three-dimensional conformal radiotherapy, brachytherapy, intensity-modulated external beam radiotherapy, and laparoscopy had gained acceptance in the treatment of localized prostate cancer; other experimental technologies such as photodynamic therapy, and microwave and radiofrequency interstitial tumor ablation are currently under investigation in early clinical trials.
Transrectal high-intensity focused ultrasound (HIFU) is a relatively new technology,  which is capable of inducing instantaneous and irreversible coagulative necrosis in all biologic tissue by thermal effect (absorption of ultrasound energy converted into heat) and cavitation. The focused ultrasound waves are emitted from a transducer and absorbed in the target area, with limited damage to the surrounding tissue, and appears to be a very attractive therapy.
Radical prostatectomy has long been regarded as the gold standard form of therapy in patients with organ-confined prostate cancer. Despite excellent long-term survival rates, surgery is associated with significant morbidity; in addition, surgery is not indicated for patients whose life-expectancy is <10 years.
HIFU is a noninvasive technique for the thermal ablation of tissue. Together with brachytherapy,  cryosurgical ablation of the prostate,  three-dimensional conformal radiotherapy, and intensity-modulated external beam radiotherapy,  it is one of the most attractive options for the noninvasive treatment of localized prostate cancer in patients with a life-expectancy of less than ten years but with a significant tumor or who do not accept the considerable morbidity associated with radical prostatectomy.
In particular, HIFU is well-suited for the anatomic position of the prostate gland, easily reached by transrectal approach.
| Background|| |
Ultrasound is a vibration, a wave with a frequency not audible by human ears; it is produced by a crystal or transducer. The ultrasonic wave deposits an amount of energy in a tissue, with the production of a thermal damage. In clinical and diagnostic practice, this thermal injury is limited.
HIFU is an acronym for high-intensity focused ultrasound: In this way, wave intensity if increased and focused to a sufficient intensity to generate tissue destruction by heat and cavitation.
At the focal point (focused ultrasound), the high intensity waves cause an intense rise in temperature, up to 100°C, resulting in protein denaturation and coagulative necrosis. At this thermal damage, the formation of cavitations by interaction with the microbubbles in the tissue contributes to coagulative necrosis.  The so called "popcorn" response is the hyperechogenicity at ultrasound scan, which is the result of local cavitation and/or formation of vapor generated gaseous bubbles at the focus.
The analysis of posttreatment specimens demonstrated an intraprostatic coagulative necrosis that leads to hemorrhagic necrosis after seven days and the formation of a scar with macrophages and deposits of hemosiderin within ten weeks. 
Ultrasound studies and parameters for treating prostate were defined in 1992; Madersbacher in 1994 was the first who used first prototype of Sonablate 200 HIFU for benign prostatic hyperplasia and in 1995 for prostate cancer in ten patients,  and the first experience on organ-confined prostate cancer with the Ablatherm device was from Gelet in 1996. 
| High-Intensity Focused Ultrasound Devices|| |
The first commercial HIFU machine, Ablatherm (EDAP TMS SA Vaulx-enVelin, France), was developed by EDAP and launched in Europe in 2001; the other device, called The Sonablate® 500 (Focus Surgery, Inc., Indianapolis, Indiana, USA), originated at Indiana University School of Medicine in Indianapolis in the 1970s, was further developed by Focus Surgery to treat prostate cancer.
Both machines are currently used in Europe and Japan, while they are not yet approved by the US FDA.
Baseline technology of both systems is the same (each employs HIFU to generate coagulative necrosis), but there are technical differences between the two devices: Difference in imaging and therapeutic transducers, position of the patient, type of software application for treatment planning, and safety monitoring.
| Ablatherm Device|| |
It uses two transducers, one for imaging at 7.5 MHz, other for treatment now at 3 MHz, with a unique focal point at 40 mms. The machine is complex, with an operative specific table in which patient is placed on his right side. After ultrasound-scanned reconstruction of the prostate gland, the surgeon plans the treatment on the screen, slice by slice, from bladder neck to prostate apex, and the computer automatically drives treatment according to a predefined algorithm (primary procedure, HIFU retreatment, radiation failure). For safety, the Ablatherm device includes real time ultrasound scan, active cooling of the rectal wall, stabilization of patient and rectal wall, and a continuous control of the distance between transducer and rectal wall. There has been increasing use of transurethral resection of prostate (TURP) before HIFU to reduce the size of the gland and to reduce postoperative obstructive symptoms.
| Sonablate Device|| |
It has a single transducer for imaging and treatment at 4 MHz, but it includes two probes with different focal points: One at 40 mms from transducer, one at 30 mms from transducer.
The machine is mobile, with a main control device and a mobile cooling system. For the procedure, patient is placed at lithotomic position. After ultrasound-scanned imaging of the prostate gland, the surgeon selects the slice and the shape for treatment, from bladder neck to prostate apex. The procedure is completely surgeon-dependent, without pre-defined treatment planning. For safety, the Sonablate device includes real time ultrasound scan with visualization of pre-operative pictures, active cooling of the rectal wall, continuous and automatic monitoring of differences between pre-operative pictures and intra-operative ones. All operative procedures with Sonablate have been standardized by Illing et al. 
The HIFU treatment is generally delivered in a day-surgery setting. All patients received an enema and an antibiotical prophylaxy. Patients are anesthetized by epidural anesthesia with sedation or general anesthesia.
A foley catheter is inserted to help identify bladder neck. The HIFU probe, covered by a condom or balloon, is manually inserted into the rectum and fixed. Degassed and cooled water circulated within the rectum to cool rectal wall and to eliminate acoustic interferences between the transducer and the rectal mucosa. After selection of the treatment zone, the catheter is removed and the treatment starts. At the end of the procedure, a transurethral catheter or a percutaneous cystostomy is inserted.
Patients are discharged the next day and received antibiotics and antinflammatory drugs for at least 21 days.
The urine drainage is removed as soon as possible.
| Contraindication|| |
Some relative or absolute contraindications need to be excluded before an HIFU procedure.
The main and obvious contraindication is accessibility: The procedure requires a transrectal approach, and all pathologic or anatomic conditions which exclude probe introduction are absolute contraindications. All local rectal disease should be carefully excluded during the rectal examination.
Another relative contraindication is the presence of major intraprostatic calcification: The treatment requires ultrasound, and calcification acts as an acoustic barrier to ultrasound progression and diffusion. A preoperative TURP can remove them, and it can remove the other relative contraindication to HIFU which are the presence of a prominent median lobe and/or a prostate of great volume: A prostate volume >40 ml should be excluded from treatment, or two HIFU session should be considered. This is the major difficulty of HIFU, to reach the anterior parts of the prostate.
| Safety|| |
Perioperative and long-term side effects following an HIFU treatment have been extensively described in many articles.
The acute urinary retention is not a perioperative complication but a normal effect induced by thermal injury and subsequent edema and swelling of the prostate, which may increase prostate volume up to 30% of its initial volume. A TURP prior to HIFU and the use of a catheter or suprapubic tube is the simplest way to solve this immediate complication.  Infact, combined with TURP, postoperative catheterization or prostate urethra or bladder neck stenosis sharply decrease.
Sloughing is the passage of necrotic tissue from the coagulated gland. During the period of sloughing, patient refers dysuria with irritative and/or obstructive symptoms, and eliminates debris through micturition. Symptomatic treatment with drugs is usually sufficient. An important complication, linked to necrotic tissue, is the high risk of urinary infection, which is usually managed by a long-term antibiotical prophilaxy.
Another frequent complication is bladder outlet obstruction by bladder neck and/or prostatic urethra stricture; it occurred in 3.6 to 24.5% of the cases,  and is usually managed with dilation. Only few cases require a TURP.
Urinary incontinence: It is usually an urge incontinence, and tends to decrease during time until the end of edema and elimination of necrotic debris. It ranges from 0.6-16%.  A stress urinary incontinence is rare, more frequent if apex is not clearly spared.
Impotence: The literature is controversial, but usually it occurs in the range of 20-49.8%. The preservation of the lateral edges of the prostate, the so called nerve-sparing HIFU, permits to spare erectile function as reported by Poissonier,  even if this decreases in erectile dysfunction rate must be balanced with a higher rate of retreatment for persistent disease.
The major complication of HIFU is uretro-rectal fistula. It usually occurs in the first two months after the procedure, and usually it occurs in patient with bladder outlet obstruction. Edema and urinary infection, together with a nonappropriate monitoring of rectal wall and a procedure in a pretreated gland (re-HIFU, HIFU for radiotherapy-relapse) are the major causes. Experience in the procedure and the addiction of cooling system and safety monitor has dramatically decreased the incidence of fistula, which now ranges between 0.5-1.2%. 
HIFU has no effect on metastasis. In the past, controversy remained surrounding the hypothesis that HIFU cavitation could lead to an increase of metastases. Most experimental studies have shown that high intensity ultrasound did not enhance the potential risk of metastasis, and paradoxically the study of Wu  showed that a substantial number of tumor patients undergoing complete HIFU may present a negative conversion of circulating tumor-specific marker as marker of circulating tumor cells, and finally, the same group  showed in a clinical model that HIFU induced a positive antitumor immunity through activation of population of CD4+ lymphocytes.
| Outcomes|| |
HIFU has been applied in most of the series, and is usually recommended for patients with localized prostate cancer, cT1-cT2 N0M0 prostate cancer who are not candidates for a radical treatment. To date, data on HIFU are not yet mature to propose it as a comparable oncological alternative to radical prostatectomy or radiotherapy for patients who are otherwise suitable candidates to these consolidated radical approach, except for the advantages of high-intensity focused ultrasound, which are the possibility of an outpatient procedure, the low morbidity and no invasivity, because HIFU is repeatable and mainly because it does not preclude subsequent radical treatments.
Several publications with Ablatherm and Sonablate devices have confirmed the HIFU efficacy and safety with short and mid-term results. However, due to short follow-up (the longest follow-up reported in the literature is to date by the group of Blana which reports outcomes at a mean follow-up of 6.4 ± 1.1 years), and different definition of end points available in the series (biochemical, disease-free survival rates with variable definitions of PSA end-points, and/or biopsy data), definitive data are not yet mature. The same problem on how interpretate oncological outcomes are for the identification of best candidates for HIFU treatment. European guidelines for prostate cancer (2008 update) do not define indication for HIFU, which is generically considered as an emerging alternative therapeutic option in the patients with clinically localized prostate cancer for low-intermediate risk patients according to D'Amico risk classification.
However, considering the characteristics of patients included in the HIFU studies, current ideal indication for HIFU as primary therapy for prostate cancer are summarized in [Table 1].
The first point for best oncological outcomes is patient's selection: In most series,  HIFU has been applied and recommended for patients with localized prostate cancer with clinical stage T1-T2 N0M0, a Gleason score ≤7, a baseline PSA value ≤15-20 ng/ml, with a prostate volume <40 ml, who are not suitable for a radical prostatectomy or who refuse to undergo for surgery and proposed as an effective alternative to radiation therapy.  Some authors  advocated HIFU plus hormone therapy as an alternative to hormonal therapy plus EBRT in high risk prostate cancer (clinical stage up to T3a, or Gleason score 8-10 or total PSA level >20 ng/ml), reporting an interesting 77% rate of negative biopsy and good results at one year follow-up.
In Mearini series,  best results are achieved for patients with low risk disease [three years biochemical no evidence of disease (bNED) 86.1%; negative biopsy 75.5%] and intermediate-risk disease (bNED 79.6%; negative biopsy 77.4%) with no statistically different results, while high and very-high risk disease presented an unacceptable risk of biochemical relapse (56.4% and 19.6%, respectively; sometimes expression of systemic disease) and/ or positive bioptic findings (64.3% and 81.2%, respectively).
The second point is definition of response.
An ideal result after HIFU, considered as an ablative procedure, is the achievement and maintenance of an undetectable PSA. However, several past studies have defined a complete response after HIFU as a negative control biopsy and a PSA level of less than 4.0 ng/ml, while other author  used progression defined as any patients with positive biopsy or a PSA more than 1 ng/ ml. Other author  defined biochemical progression as a PSA rise over 0.4 ng/ ml, but now the most accepted definition of disease-free status is the ASTRO criteria,  i.e., three consecutive PSA increases after the PSA nadir have been reached. According to the ASTRO definition of bNED, Uchida et al.,  reported an overall biochemical disease-free rate of 75%, with a clear distinction for low risk disease (84%) vs. 69% and 51% for intermediate and high risk diseases, respectively. Other author used the new ASTRO-Phoenix definition of biochemical failure (i.e., PSA nadir plus 2 ng/ ml): According to this definition, overall five-years bNED reached was 77%  in patients with low-intermediate risk prostate cancer. According to ASTRO-Phoenix criteria, in Mearini experience,  overall bNED is 78.2%, similar to other experience with HIFU, and the results for low risk and intermediated risk group are comparable to the outcome of patients treated with brachytherapy  [Table 2].
Response rate are defined according to PSA level, ASTRO criteria (1997), or ASTRO-Phoenix criteria (2005). [Table 3] shows disease-free survival rate according to different definitions of response.
A positive finding at prostate biopsy is an indicator of local persistence-relapse, and it is obviously another indicator of HIFU failure.
Disease control using negative biopsy findings, usually measured at 3-6 months after HIFU, in most series was observed between 66-93.4%, with difference between low/ intermediate risk and high risk patients [Table 4].
Outcomes in terms of biochemical-free survival or negative biopsy obviously varied according to patients selection, i.e., baseline PSA values, stage of disease, number of positive sextant biopsies, Gleason score.
The third point is the definition of a surrogate for predicting treatment failure. Prognostic factors to estimate the risk of treatment failure would be useful for the clinician in informing patient regarding the likelihood of requiring salvage treatment. Most authors , agree that PSA nadir (i.e., the lowest postoperative PSA value, usually achieved within 3-4 months) shows a clear and intuitive association with the risk of treatment failure. PSA nadir was found to be strongly associated with preoperative baseline PSA (explained by the increasing probability of extraprostatic disease with increasing PSA level) and prostate volume (large prostate remnants will produce PSA). PSA nadir can be used to predict the risk of residual disease, showed by six months postoperative prostate biopsy. However, the correct PSA-nadir cut-off has not been yet defined [Table 5], even if, like for radical prostatectomy, a value <0.20 ng/ml seems to be the best predictor of disease persistence.
In most contemporary series, a PSA nadir <0.5 ng/ml, a good prognostic indicator of success, is obtained in a range of 61-84%.
In Mearini experience,  a PSA nadir >0.40 ng/ml, correlates with biochemical relapse or positive findings at prostate biopsy, but surprisingly it did not correlate at univariate analysis with any preoperative variable (baseline PSA, prostate volume, stage, Gleason score). According to risk stratification, PSA nadir showed a linear trend, which approaches statistical significance, with an increasing value for high-very high risk disease.
High-intensity focused ultrasound retreatment
In some cases and in the presence of a positive control biopsy, HIFU will have to be repeated. The safety profile of HIFU permits a no limited number of sessions, and up to five sessions have been described. 
However, the safety of a re-HIFU has been subject of discussion in the panorama of HIFU users; in particular, rate of incontinence and erectile dysfunction seems to be increased by another HIFU session, and also for urethral stenosis.
Salvage high-intensity focused ultrasound
HIFU should be proposed as salvage after external beam radiation therapy EBRT or failure after brachytherapy, as 20-50% of the patients may experience a PSA failure over time.
Of these subject, about one-third have a true isolated local recurrence, potentially cured by a local salvage approach, even if patients with relapse after EBRT generally have a very poor prognosis, and the therapeutic options are limited.
However, before local salvage approach, true local recurrence must be documented by prostate biopsies.
Gelet in 2004,  Chaussy in 2006,  and Murat in 2007 and 2008 , used HIFU as local treatment of biopsy-proven recurrence after EBRT, with a local control rate of 80%, 74%, and 73%, respectively, and with best result for patients with initial low risk or at least intermediate risk group characteristics. The use of correct indication for best results are particularly important in the setting of HIFU after EBRT or brachytherapy, because complications rate are significant, as fistula rate reaches the incidence of 7% and incontinence rate grows up to 50%, with a lot of cases of grade 3 stress incontinence.
Zacharakis, in 2008,  reported a retrospective evaluation of results and safety of HIFU-Sonablate in 31 patients with biopy-proven recurrence after EBRT, with a bNED of 71%. Urethral stricture rate requiring resection was reported in 36% of the cases, two patients developed grade 3 urinary incontinence and 2 a recto-urethral fistula (7%) [Table 6].
| Future|| |
The present of HIFU is to define its role in management of localized prostate cancer as primary treatment and as therapeutic option for radiation failure.
The future of HIFU will be in defining imaging modalities, the evaluation of adjuvant therapy, its use in locally advanced prostate cancer, and finally its use as a focal therapy.
HIFU is an ultrasound-guided technology, and now the presence of a color Doppler in the new software of Sonablate should help identify neurovascular bandles to spare sexual function. However, the most intriguing new is the use of HIFU MRI-guided, as a prototype of endorectal probe coupled with focused ultrasound has been develop and presented at the 2005 international society for magnetic resonance in Medicine in Miami.
New imaging methods as fat-saturated gadolinium-enhanced MRI can demonstrated accurately the extent of tissue damage induced by HIFU, and multi-sequence MRI of prostate gland should help physician to discriminate between local and systemic failure after an HIFU procedure, reducing the significance of a false-negative data of a post-operative prostate biopsy in a patients with a PSA rising.
Like for radiation therapy, the neoadjuvant or adjuvant use of hormone manipulation has not been completely evaluated, apart from an experience of Ficarra  who proposed a 3-year hormonal therapy with LH-RH blockade in the setting of high risk prostate cancer according to D'Amico risk classification, or the experimental findings of Paparel  with the use in a rat model of the synergic positive effects of HIFU and docetaxel.
The real interesting setting of HIFU will be the evaluation of its use as focal therapy in case of accurate and reliable diagnosis of monofocal prostate cancer. This involves the treatment of only the areas of prostate cancer, so sparing as much as possible the 'health' gland, sparing continence and potency as much as possible.
This interesting use of focal HIFU starts from the consideration that 10-40% of men with prostate cancer will have monofocal disease, and some patients with multifocal disease have only a so called 'index lesion' or just one monofocal clinically significative disease. The problem of focal HIFU is that monofocal prostate cancer cannot be reliably localized with current tests or intervention, and it should be overtake by a saturation biopsy and/or the use of multi-sequence magnetic resonance imaging. Previous experience with hemiablation cryotherapy by Onik  and Lambert  had shown feasibility of focal treatment prostate cancer, with interesting short terms outcomes and high rate of post-operative erectile function (86% and 71%, respectively).
The only paper on hemiablative HIFU using the Sonablate is from Muto,  which used HIFU as in 29 patients with biopsy-proven unilateral disease, sparing one half of the transition zone, controlateral to the disease. But his experience is too early and not conclusive.
The prospect of using HIFU as focal therapy  lies on accurate localization of at least significative malignant foci, and this requires a state of the art diagnostic and therapeutic imaging, and this will be the future.
| Conclusions|| |
HIFU is a relatively new procedure of prostate cancer treatment and surely it could become one choice for patient with localized prostate cancer.
HIFU is already approved in Canada, Europe and Asia, and has gained FDA acceptance for a phase III clinical trial.
Such as others mini-invasive treatment, HIFU needs a careful selection of patients (localized prostate cancer, low risk of nodal or systemic disease, small prostate gland) and it could be reserved for patients with low-intermediate risk disease as defined by D'Amico risk stratification. ASTRO or Phoenix criteria, together with prostate biopsy and PSA nadir are the best surrogate to define disease control.
However, only more extensive follow-up study, and randomized control trial comparing HIFU with other form of treatment will definitively place HIFU in the armamentarium of prostate cancer control, because the current evaluation of oncological outcome is biased by the heterogeneity of populations in which HIFU has been used along with several definitions of treatment failure.
As the noninvasive treatment of prostate cancer, HIFU, has advantages and disadvantages, which should be considered in the decision making process [Table 7].
| References|| |
|1.||Yancik R. Population aging and cancer: A cross-national concern. Cancer J 2005;11:437-41. |
|2.||Lynn LG, Putnam TJ. Histological and cerebral lesions produced by focused ultrasound. Ann J Pathol 1944;20:637-49. |
|3.||Jo Y, Junichi H, Tomohiro F, Yoshinari I, Masato F. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: Effects on health-related quality of life. BJU Int 2005;96:43-7. |
|4.||Pontones Moreno JL, Morera Martínez JF, Vera Donoso CD, Jiménez Cruz JF. Cryosurgery in the management of prostate cancer. Actas Urol Esp 2007;31:211-32. |
|5.||Su AW, Jani AB. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol 2007;30:215-9. |
|6.||Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A. In vivo effects of high-intensity ultrasound on prostate adenocarcinoma. Cancer Res 1992;52:6353-7. |
|7.||Madersbacher S, Kratzik C, Marberger M. Prostatic tissue ablation by transrectal high intensity focused ultrasound: Histological impact and clinical application. Ultrason Sonochem 1997;4:175-9. |
|8.||Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995;55:3346-51. |
|9.||Gelet A, Chapelon JY, Bouvier R, Souchon R, Pangaud C, Abdelrahim AF, et al. Treatment of prostate cancer with transrectal focused ultrasound: Early clinical experience. Eur Urol 1996;29:174-83. |
|10.||Illing RO, Leslie TA, Kennedy JE, Calleary JG, Ogden CW, Emberton M. Organ-confined prostate cancer: A proposed standard for the conduct of therapy. BJU Int 2006;98:1187-92. |
|11.||Chaussy C, Thüroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003;4:248-52. |
|12.||Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, et al. Eight years experience with high intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008;72:1329-33. |
|13.||Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381-7. |
|14.||Thüroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, et al. High-intensity focused ultrasound and localized prostate cancer: Efficacy results from the European multicentric study. J Endourol 2003;17:673-7. |
|15.||Wu F, Wang ZB, Jin CB, Zhang JP, Chen WZ, Bai J, et al. Circulating tumor cells in patients with solid malignancy treated by high-intensity focused ultrasound. Ultrasound Med Biol 2004;30:511-7. |
|16.||Wu F, Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H, et al. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol 2004;30:1217-22. |
|17.||Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004;63:297-300. |
|18.||Murat FJ, Poissonnier L, Pasticier G, Gelet A. High-intensity focused ultrasound (HIFU) for prostate cancer. Cancer Control 2007;14:244-9. |
|19.||Ficarra V, Antoniolli SZ, Novara G, Parisi A, Fracalanza S, Martigono G, et al. Short-term out come after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU 2006; 98: 1193-8. |
|20.||Mearini L, D'Urso L, Collura D, Zucchi A, Costantini E, Formiconi A, et al. Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: A preliminary report on the Italian experience. J Urol 2009;181:105-11. |
|21.||Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035-41. |
|22.||Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using hig-intensity focused ultrasound. BJU Int 2006;97:56-61. |
|23.||Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, et al. First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008;53:1194-201. |
|24.||Beyer DC. The evolving role of prostate brachytherapy. Cancer Control 2001;8:163-70. |
|25.||Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W. Brachytherapy for carcinoma of the prostate: Techniques, patient seletion, and clinical outcomes. Semin Radiat Oncol 2002;12:81-94. |
|26.||Zelefsky MJ, Yamada Y, Cohen GN, Shippy A, Chan H, Fridman D, et al. Five-year outcome of intraoperative conformal permanente I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007;67:65-70. |
|27.||Uchida T, Ohkusa H, Yamashita H, Shoji S, Nagata Y, Hyodo T, et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006;13:228-33. |
|28.||Misraï V, Rouprêt M, Chartier-Kastler E, Comperat E, Renard-Penna R, Haertig A, et al. Oncological control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J Urol 2008;26:481-5. |
|29.||Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006;98:537-9. |
|30.||Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, et al. PSA nadir is a significant predictor if treatment failure after high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. Eur Urol 2008;53:547-53. |
|31.||Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B. Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006;24:585-90. |
|32.||Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouvière O, Curiel L, et al. Local recurrence of prostate cancer after external beam radiotherapy: Early experience of salvage therapy using high-intenbsity focused ultrasonography. Urology 2004;63:625-9. |
|33.||Chaussy C, Thüroff S, Bergsdorf T. Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option in German. Urologe A 2006;45:1271-5. |
|34.||Murat FJ, Poisonnier L, Rouviere O. Salvage high intensity focused ultrasound (HIFU) treatment for recurrent prostate cancer after radiation therapy: High efficacy in patients with good initial prognosis. J Urol 2007;177:591. |
|35.||Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, et al. Mid-term Results Demonstrate Salvage High-Intensity Focused Ultrasound (HIFU) as an Effective and Acceptably Morbid Salvage Treatment Option for Locally Radiorecurrent Prostate Cancer. Eur Urol 2009;55:640-9. |
|36.||Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, et al. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int 2008;102:786-92. |
|37.||Paparel P, Curiel L, Chesnais S, Ecochard R, Chapelon JY, Gelet A. Synergistic inihinitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int 2005;95:881-5. |
|38.||Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. "Male lumpectomy": Focal therapy for prostate cancer using cryoablation. Urology 2007;6:16-21. |
|39.||Lambert EH, Bolte K, Masson P, Katz AE. Focal cryosurgery: Encouraging health outcomes for unifocal prostate cancer. Urology 2007;69:1117-20. |
|40.||Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S. Focal therapy with high-intensity focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 2008;38:192-9. |
|41.||Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4:632-42. |
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7]
|This article has been cited by|
||Low Temperature Plasma: A Novel Focal Therapy for Localized Prostate Cancer?
| ||Adam M. Hirst,Fiona M. Frame,Norman J. Maitland,Deborah O’Connell |
| ||BioMed Research International. 2014; 2014: 1 |
|[Pubmed] | [DOI]|
||Understanding prostate cancer
| ||Brown, C.H. |
| ||Pharmacy Times. 2012; 78(9) |
||Experimental investigation of MRgHIFU sonication with interleaved electronic and mechanical displacement of the focal point for transrectal prostate application
| || Petrusca, L., Ngo, J., Brasset, L., Blanc, E., Murillo, A., Auboiroux, V., Cotton, F., (...), Salomir, R. |
| ||Physics in Medicine and Biology. 2012; 57(15): 4805-4825 |
||Experimental investigation of MRgHIFU sonication with interleaved electronic and mechanical displacement of the focal point for transrectal prostate application
| ||Lorena Petrusca,Jacqueline Ngo,Lucie Brasset,Emmanuel Blanc,Adriana Murillo,Vincent Auboiroux,François Cotton,Jean-Yves Chapelon,Rares Salomir |
| ||Physics in Medicine and Biology. 2012; 57(15): 4805 |
|[Pubmed] | [DOI]|
||Prostate cancer overview
| || Dunn, M.W., Kazer, M.W. |
| ||Seminars in Oncology Nursing. 2011; 27(4): 241-250 |
||Benign prostatic hyperplasia: An overview of existing treatment
| ||Dhingra, N., Bhagwat, D. |
| ||Indian Journal of Pharmacology. 2011; 43(1): 6-12 |
||Prostate Cancer Overview
| ||Mary Weinstein Dunn,Meredith Wallace Kazer |
| ||Seminars in Oncology Nursing. 2011; 27(4): 241 |
|[Pubmed] | [DOI]|